In accordance with this notion, we recently reported CML immune subversion of iNKT-cell activities in CML patients at diagnosis (22, 27), including reduced or suppressed expression of perforin, CD95L, and (PLZF), a transcription factor required for maintenance of iNKT cell functions (28, 29). The gene discussed is ZBTB16; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.